4-{[5-(chloromethyl)-1H-imidazol-1-yl]methyl}benzonitrile | 186202-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{[5-(chloromethyl)-1H-imidazol-1-yl]methyl}benzonitrile
• 英文别名: 1-(4-cyanobenzyl)-5-chloromethylimidazole；5-chloromethyl-1(4-cyanobenzyl)imidazole；1-(4-cyanobenzyl)-5-(chloromethyl)-imidazole；1-(4-Cyanobenzyl)-5-(chloromethyl)-imidazol；1-(4-Cyanobenzyl)-5-(chloromethyl)imidazole；4-[[5-(chloromethyl)imidazol-1-yl]methyl]benzonitrile
• CAS: 186202-42-6
• 化学式: C₁₂H₁₀ClN₃
• 分子量: 231.685
• InChiKey: NCJBTZGRLAGOIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  41.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-{[5-(chloromethyl)-1H-imidazol-1-yl]methyl}benzonitrile 在 盐酸 、 甲醇 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 、 乙腈 为溶剂， 反应 31.0h， 生成 1-[1-(4-cyanobenzyl)-1H-imidazol-5-yl]methyl-4-(2,3-dimethoxybenzoyl)-1,4-diazepane dihydrochloride
  参考文献：
  名称：

  Potent Farnesyltransferase Inhibitors with 1,4-Diazepane Scaffolds as Novel Destabilizing Microtubule Agents in Hormone-Resistant Prostate Cancer

  摘要：

  A new class of potent farnesyltransferase inhibitors based on a 1,4-diazepane scaffold was synthesized with protein farnesyltransferase inhibition potencies in the low nanomolar range. The compounds block the growth on two hormone-resistant tumor prostatic cell lines (DU145 and PC3). The advanced cellular evaluation of the more potent farnesyltransferase inhibitors was explored and revealed a disorganization of tubulin in PC3 cells.

  DOI：

  10.1021/jm101067y
• 作为产物：
  描述：

  1-(4-氰基苄基)-1H-5-羟基甲基咪唑 以 氯化亚砜 为溶剂， 生成 4-{[5-(chloromethyl)-1H-imidazol-1-yl]methyl}benzonitrile
  参考文献：
  名称：

  Inhibitors of farnesyl-protein transferase

  摘要：

  本发明涉及抑制法尼基-蛋白转移酶（FTase）和致癌基因蛋白Ras的法尼醇化的化合物。该发明进一步涉及含有本发明化合物的化疗组合物以及抑制法尼基-蛋白转移酶和致癌基因蛋白Ras的方法。

  公开号：

  US05817678A1

文献信息

• Method of treating cancer
  申请人：——

  公开号：US20030220241A1

  公开（公告）日：2003-11-27

  The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

  本发明涉及使用一种PSA共轭物和一种前脂蛋白转移酶抑制剂的组合治疗癌症的方法，该方法包括向所述哺乳动物施用来自以下组中选择的至少两种治疗剂的量，所述组包括一种PSA共轭物和一种前脂蛋白转移酶抑制剂，所述治疗剂可以顺序给药或同时给药。该发明还涉及制备这种组合物的方法。
• Inhibitors of farnesyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US05756528A1

  公开（公告）日：1998-05-26

  The present invention comprises low molecular weight peptidyl compounds that inhibit the farnesyl-protein transferase. Furthermore, these compounds differ from the mono- or dipeptidyl analogs previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.

  本发明包括抑制法尼基-蛋白转移酶的低分子量肽类化合物。此外，这些化合物与先前描述的作为法尼基-蛋白转移酶抑制剂的单肽或二肽类似物不同之处在于它们不含硫醇基团。缺乏硫醇基团在动物体内具有改善药代动力学行为、预防硫醇依赖性化学反应（如快速自氧化和与内源硫醇形成二硫键）以及减少全身毒性方面提供了独特优势。本发明还包括含有这些法尼基转移酶抑制剂的化疗组合物以及其生产方法。
• Inhibitors of prenyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US06376496B1

  公开（公告）日：2002-04-23

  The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.

  这项发明涉及含有哌嗪的化合物，可以抑制前萜基蛋白转移酶，包括法尼基蛋白转移酶和戊二烯基蛋白转移酶I型。这种治疗性化合物在癌症治疗中很有用。
• Synthesis and activity of 1-aryl-1′-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors
  作者：Qun Li、Gary T. Wang、Tongmei Li、Stephen L. Gwaltney、Keith W. Woods、Akiyo Claiborne、Xilu Wang、Wendy Gu、Jerry Cohen、Vincent S. Stoll、Charles Hutchins、David Frost、Saul H. Rosenberg、Hing L. Sham

  DOI：10.1016/j.bmcl.2004.08.011

  日期：2004.11

  potent and selective farnesyltransferase inhibitors (FTIs) by transposition of the D-ring to the methyl group on the imidazole of the previously reported FTIs 3. Several compounds such as 4h and 5b demonstrate superior enzymatic activity to the current benchmark compound tipifarnib (1) with IC(50) values in the lower subnanomolar range, while maintaining excellent cellular activity comparable to tipifarnib

  通过将D环转位至先前报道的FTI 3的咪唑上的甲基，已设计并合成了一系列含咪唑的甲基醚（4-5），作为有效的和选择性的法呢基转移酶抑制剂（FTI）。例如4h和5b表现出比当前基准化合物Tipifarnib（1）更高的酶活性，IC（50）值在较低的纳摩尔范围内，同时保持了与Tipifarnib相当的优异细胞活性。这些化合物的特征是简单，易于制造，并且不涉及手性中心。
• Farnesyltransferase inhibitors
  申请人：——

  公开号：US20030199544A1

  公开（公告）日：2003-10-23

  Compounds having the formula 1 are farnesyltransferase inhibitors. Also disclosed are methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds.

  具有化学式1的化合物是法尼基转移酶抑制剂。还公开了制备这些化合物的方法、含有这些化合物的药物组合物，以及使用这些化合物进行治疗的方法。